Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy

Metabolism. 2009 Aug;58(8):1185-90. doi: 10.1016/j.metabol.2009.03.019. Epub 2009 Jun 18.

Abstract

The aim of the present study was to determine whether red or white wine affects urinary protein, 8-hydroxydeoxyguanosine (8-OHdG), and liver-type fatty acid-binding protein (L-FABP) excretion in type 2 diabetic nephropathy patients. Twenty-four type 2 diabetes mellitus patients with nephropathy were randomly allocated to drink a 118-mL (4-oz) glass of red wine (n = 12, group A) or white wine (n = 12, group B) daily for 6 months. Twelve type 2 diabetes mellitus patients with nephropathy who did not drink any wines served as control subjects (group C). Serum creatinine, 24-hour creatinine clearance, hemoglobin A(1c), urinary protein, urinary 8-OHdG, and urinary L-FABP were measured before and 3 and 6 months after the start of the study. In groups A, B, and C, serum creatinine, 24-hour creatinine clearance, and hemoglobin A(1c) changed little during the experimental period. However, urinary protein, 8-OHdG, and L-FABP excretions were significantly decreased at 3 (P < .05) and 6 months (P < .01) compared with the baseline values in group A. In contrast, these markers changed little during the experimental period in groups B and C. Thus, these urinary markers were significantly lower in group A than in groups B and C at 3 and 6 months. These results suggest that red wine is renoprotective whereas white wine has no such effect in type 2 diabetes mellitus patients with nephropathy. The renoprotective effect of red wine may be due in part to its ability to reduce oxidative stress.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Biomarkers / urine
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / urine
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / urine*
  • Fatty Acid-Binding Proteins / urine*
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Middle Aged
  • Oxidative Stress*
  • Proteinuria / prevention & control
  • Time Factors
  • Wine*

Substances

  • Antihypertensive Agents
  • Biomarkers
  • FABP1 protein, human
  • Fatty Acid-Binding Proteins
  • Hypoglycemic Agents
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine